<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Anti-endothelial cell activity is partly due to <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> (aPLA) because: a) the two types of antibodies are present in patients with <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue diseases</z:e> and <z:chebi fb="0" ids="28494">cardiolipin</z:chebi>-binding monoclonal antibodies recognize endothelial cells (EC); b) anionic <z:chebi fb="1" ids="16247">phospholipids</z:chebi> are detectable on the outer face of the EC membrane <z:chebi fb="23" ids="18059">lipid</z:chebi> bilayer and an anti-beta 2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (beta 2-GPI) monoclonal antibody binds to EC; c) the binding of aPLA to EC and the functional affinity of this binding are dependent on the presence of beta 2-GPI; d) anti-EC antibodies trigger the expression of anionic <z:chebi fb="1" ids="16247">phospholipids</z:chebi> on the outer leaflet of the EC membrane </plain></SENT>
</text></document>